The Nama Traditional Leaders Association (NTLA) and the Ovaherero Traditional Authority (OTA) have strongly rejected the impending conclusion of the joint declaration ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

NDAQ:NTLA) Shareholders that lost money on Intellia Therapeutics, Inc. (NTLA) should contact Levi & Korsinsky about ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research ...

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...